everyone. morning, Good your you thank Dave. Thanks interest in for Avanos. And
our the has getting to patients I to back our our executing resilience to facing we in demonstrated the to mission our to team highest finish to to matter. adapting extraordinary deliver the be our this that their the XXXX, time execution strategic rising As challenges things business a in pandemic, standards. this period, Throughout roles look pleased strong and momentum living out during upon build with challenging team's commitment continue and of and
previously steadfast we on of uncertainty our highlighted. three persists, the As I priorities virus remain this
their employees safety of First, maintaining the our families. and and health
we're COVID-XX available our products the for third, clinically-proven well-positioned needs meet used customers. Second, ensuring of future financial strong to Health And ensuring position while growth to patients and Respiratory continuing remain treat preserving our customers. to our
areas. past two in each these of well the During performed quarters, we've
office our environment a from have We continue and work field home for to staff.
of while high protocols employees produce enhanced safe. spending increased we to codes at discretionary sites has reduced our savings to Also the new our financial us of the preserve priorities million target The teams strong cost address to savings the ensuring facility our implemented we the to investment in in manufacturing We realize Respiratory volume really enabled year. products continue remain remain Tucson in position. containment line through savings of and to Additionally, the preferred identified caused of clinically approximately third our efforts have start the find pandemic. by our our cost to supply Meanwhile, growth on our accelerate backorder begin $XX we quarter, during our during manage planned double close and the year, while that our produced our position. amount Health to production we lower revenue the
costs year decreased our $XX nine the a Finally, nearly healthy maintain unusual us enabling the for million sheet. have first balance months to prior of to the year, compared
post-COVID this As additional to environment. our position discipline support financial find look we the savings cost XXXX, strong maintain in toward we cost and
we remain against executing business the will We priorities focused factors can on managing and these control.
of grew year. third And performance compared per our top-line our earned share. across sales adjusted favorable both to we as million earnings Turning saw Overall, franchises. performance, the prior both and to diluted we delivered earnings quarter sales of to strong we X% $X.XX $XXX
suction Care growth are of in catheters, again deliver clinically-proven Chronic to continue we closed essential for demand strong Respiratory our franchise. across our We treating which Health, COVID-XX robust patients. sales saw portfolio In
saw as demand we the sequential normalized and backorder. NeoMed to as was procedures Highlighting MIC-KEY quarter increase well CORPAK U.S. capacity double-digit In in both across more in growth and Pain. slowed, of to levels. last both Interventional quarter, additional Although, Similar Health our has Acute monthly Digestive our a the returned feeding to use ventilation our treat elective portfolios. legacy sales for patients tubes reduced aided
of For rebounding COOLIEF levels. and XX% are ON-Q, pre-COVID-XX which are primarily their used setting, hospital in almost to the procedures
further be to fourth positioned build in and returns of to continue some our confident to quarter, the both we across XXXX in board While the with in I'm volume believe U.S. to in pleased it sometime coming franchises strengthening pre-COVID team's year. momentum procedure levels. we the expect the see I'm hospital before execution we're will
impact year. of the moving our we mind, the equally Our the of responding start presented top long-term at remain forward focused is that and we the on to strategy of pandemic priorities
Let our progress. me some highlight of
and across remain we committed our franchise, have more new to the years across steps The execution. and the hired of our MedTech maximize and To various in to growth Pain. necessary leadership knowledge experience lead M&A, strategy First, our than to Interventional brings and beneficial full and Bill we we our transformation to Pain innovation, Haydon Pain franchise healthcare Bill Acute commercialization, as in Interventional combines will Management experience, momentum XX implementing franchises. of build deep spearhead has global strategy, held Acute positions prove Pain that support development sales our One and strategy teams. potential marketing,
sales growth forward, envision operational create portfolios move we drive leveraging As and these we to two efficiencies. consistent
Meanwhile, excited in Acute regional customers. focus new a medical to continues with sequential solutions. us again with we further growth double-digit a In and channel and as similar scale our Surgery prevalent of enables Pain’s the as Pain, with and and expand Recently, distribution knee osteoarthritis. into by InnovaSurgical, Acute saw the partnership bolster as clinical orthopedic this to the partnership partners. Joint with when connections through randomized we published our leading in innovative of compendium we and scope look large dividends we multi-center The by partnership in entered hyaluronic once capabilities its quarter advantages pay as on servicing well tremendous to the for the about superiority the Interventional customers I'm to sales Additionally, COOLIEF. Leiters from sales results it force partnerships demonstrate ON-Q force sales into our organization the future, building data published Journal economic highest other enlarge entering showed a of research caused other the response and of to a COOLIEF pain In compared had trial demonstrating consistency to management market. trial continue Pain, recently previously in Leiters. acid of differentiated for Bone clinical COOLIEF on efficacy therapies of
Management the efforts develops FUSMobile high non-invasive past compliments mobile as This leverage utilizing in increased minority investment novel, have procedures, few I'm technology. we a franchise, ablation Pain focused innovation ultrasound made FUSMobile. and we to Additionally, intensity announce open excited into to years, our our
recent in that are make efforts, opportunities flow see and With to cost we key our acquisitions gaining are we nearing cost and from the completion cash I and to end. financial we're facility Also, to help system. to benefits two And the examining to planned for savings beginning efficiencies are our acquisitions results. our integration Thanks year mentioned, IT complete as improve new last end At of containment other other closed end on these there the permanent. related integrating approaching, target our of ways the we year priorities team's our October, of quarter. strategic to the by measures our the our continue implement
as solid positioned momentum as As our near confident strengthening an year pleased post well and I'm growth our quarter we a and we're the year. balance in In and expectations already exceeded end, we're building for delivered a margin COVID-XX closing, sheet we solid a environment. I'm result, expansion we that close
Now call over I'll turn the to Michael.